Emergency Preparedness & Response
- Specific Hazards
- Bioterrorism
- A–Z
- Anthrax
- What You Need To Know
- Mail Handlers
- Questions & Answers
- Additional Fact Sheets & Overviews
- Cutaneous Anthrax
- Diagnosis
- Environment
- Exposure Management
- Infection Control
- Lab Testing
- Images
- Preparation & Planning
- References
- Surveillance & Investigation
- Training & Education
- Treatment
- Vaccination
- Work Safety
- Arenaviruses
- Botulism
- Brucella
- Cholera
- Ebola virus
- E. coli
- Food safety threats
- Glanders
- Lassa fever
- Marburg virus
- Melioidosis
- Plague
- Q fever
- Salmonella
- Shigella
- Smallpox
- Smallpox Basics
- Vaccine Basics
- Clinicians
- Vaccination Q & A (for professionals)
- Health Officials
- People Selected for Response Teams
- Diagnosis/
Evaluation - Lab Testing
- Infection Control
- Surveillance & Investigation
- Preparation & Planning
- Response
- Vaccination
- Images
- Medical Management
- Training & Education
- References
- Tularemia
- Typhoid fever
- Viral hemorrhagic fevers
- Anthrax
- List by Category
- Fact Sheets
- Case Definitions
- Training
- Surveillance
- Preparation & Planning
- First Responders
- Lab Info
- A–Z
- Chemical
- A–Z
- Abrin
- Adamsite
- Ammonia
- Arsenic
- Arsine
- Barium
- Benzene
- Brevetoxin
- Bromine
- BZ
- Carbon monoxide
- Chlorine
- Chromium
- Colchicine
- Cyanide
- Digitalis
- Ethylene glycol
- Hydrazine
- Hydrofluoric acid
- Hydrogen chloride
- Lewisite
- Melamine
- Mercury
- Methyl bromide
- Methyl isocyanate
- Nicotine
- Nitrogen mustard
- Opioids
- Organic solvents
- Osmium tetroxide
- Paraquat
- Phosgene
- Phosgene oxime
- Phosphine
- Phosphorus
- Ricin
- Sarin
- Saxitoxin
- Selenium
- Sodium azide
- Sodium monofluoroacetate
- Soman
- Strychnine
- Sulfur mustard
- Sulfuryl Fluoride
- Super Warfarin
- Tabun
- Tetrodotoxin
- Thallium
- Trichothecene
- Unidentified Chemical
- VX
- List by Category
- Chemical-Specific Fact Sheets
- Toxicology FAQs
- Case Definitions
- Toxic Syndrome Descriptions
- Toxicological Profiles
- Training
- First Responders
- Medical Management
- Emergency Response Cards
- Lab Info
- Surveillance
- Preparation & Planning
- A–Z
- Gulf Oil Spill 2010
- Radiation
- Mass Casualties
- Natural Disasters & Severe Weather
- Recent Outbreaks & Incidents
- Bioterrorism
- Preparedness for All Hazards
- Children
- Clinician Resources
- About COCA
- COCA Partner Organizations
- COCA Conference Calls
- Conference Calls - 2013
- Conference Calls - 2012
- Conference Calls - 2011
- Conference Calls - 2010
- June 3, 2010
- June 9, 2010
- June 22, 2010
- July 8, 2010
- July 27, 2010
- August 3, 2010
- August 17, 2010
- August 30, 2010
- September 2, 2010
- September 16, 2010
- September 21, 2010
- September 22, 2010
- October 1, 2010
- November 2, 2010
- November 9, 2010
- November 23, 2010
- December 2, 2010
- December 7, 2010
- December 14, 2010
- December 15, 2010
- Continuing Education Credit for COCA Calls
- Updates & Reminders
- Reminders - 2012
- Reminders - 2011
- Reminders - 2010
- Updates - 2013
- Updates - 2012
- January 3, 2012
- January 17, 2012
- January 30, 2012
- February 13, 2012
- February 27, 2012
- March 12, 2012
- March 26, 2012
- April 9, 2012
- April 23, 2012
- May 7, 2012
- May 21, 2012
- June 4, 2012
- June 18, 2012
- July 2, 2012
- July 16, 2012
- July 30, 2012
- August 13, 2012
- August 27, 2012
- September 10, 2012
- September 24, 2012
- October 8, 2012
- October 22, 2012
- November 5, 2012
- November 19, 2012
- December 3, 2012
- Updates - 2011
- January 3, 2011
- January 18, 2011
- January 31, 2011
- February 14, 2011
- February 28, 2011
- March 14, 2011
- March 21, 2011
- April 4, 2011
- April 11, 2011
- April 25, 2011
- May 9, 2011
- May 23, 2011
- June 6, 2011
- June 20, 2011
- July 5, 2011
- July 18, 2011
- August 1, 2011
- August 15, 2011
- August 29, 2011
- September 12, 2011
- September 26, 2011
- October 11, 2011
- November 7, 2011
- November 21, 2011
- December 5, 2011
- December 19, 2011
- Updates - 2010
- Join the COCA Mailing List
- Conference & Training Opportunities
- Emergency Preparedness and Response Training Resources
- Communicating in the First Hours
- Coping with a Disaster
- Crisis & Emergency Risk Communication (CERC)
- Health Alert Network (HAN)
- HAN Jurisdictions
- HAN Message Types
- Sign-Up for HAN Updates
- HAN Archive
- 2013
- 2012
- 2011
- 2010
- 2009
- 2008
- 2007
- 2006
- 2005
- 2004
- HAN00219
- HAN00218
- HAN00217
- HAN00216
- HAN00215
- HAN00214
- HAN00213
- HAN00212
- HAN00211
- HAN00210
- HAN00209
- HAN00208
- HAN00207
- HAN00206
- HAN00205
- HAN00204
- HAN00203
- HAN00202
- HAN00201
- HAN00200
- HAN00199
- HAN00198
- HAN00197
- HAN00196
- HAN00195
- HAN00194
- HAN00193
- HAN00192
- HAN00191
- HAN00190
- HAN00189
- HAN00188
- HAN00187
- HAN00186
- HAN00185
- HAN00184
- HAN00183
- HAN00182
- HAN00181
- 2003
- HAN00180
- HAN00179
- HAN00178
- HAN00177
- HAN00176
- HAN00175
- HAN00174
- HAN00173
- HAN00172
- HAN00171
- HAN00170
- HAN00169
- HAN00168
- HAN00167
- HAN00166
- HAN00165
- HAN00164
- HAN00163
- HAN00162
- HAN00161
- HAN00160
- HAN00159
- HAN00158
- HAN00157
- HAN00156
- HAN00155
- HAN00154
- HAN00153
- HAN00152
- HAN00151
- HAN00150
- HAN00149
- HAN00148
- HAN00147
- HAN00146
- HAN00145
- HAN00144
- HAN00143
- HAN00142
- HAN00141
- HAN00140
- HAN00139
- HAN00138
- HAN00137
- HAN00136
- HAN00135
- HAN00134
- HAN00133
- HAN00132
- HAN00131
- HAN00130
- HAN00129
- HAN00128
- HAN00127
- HAN00126
- HAN00125
- HAN00124
- HAN00123
- HAN00122
- HAN00121
- HAN00120
- HAN00119
- HAN00118
- HAN00117
- HAN00116
- HAN00115
- HAN00114
- HAN00113
- HAN00112
- HAN00111
- HAN00110
- HAN00109
- HAN00108
- 2002
- HAN00107
- HAN00106
- HAN00105
- HAN00104
- HAN00103
- HAN00102
- HAN00101
- HAN00100
- HAN00099
- HAN00098
- HAN00097
- HAN00096
- HAN00095
- HAN00094
- HAN00093
- HAN00092
- HAN00091
- HAN00090
- HAN00089
- HAN00088
- HAN00087
- HAN00086
- HAN00085
- HAN00084
- HAN00083
- HAN00082
- HAN00081
- HAN00080
- HAN00079
- HAN00078
- HAN00077
- HAN00076
- HAN00075
- HAN00074
- HAN00073
- HAN00072
- HAN00071
- HAN00070
- HAN00069
- HAN00068
- HAN00067
- 2001
- HAN00066
- HAN00065
- HAN00064
- HAN00063
- HAN00062
- HAN00061
- HAN00060
- HAN00059
- HAN00058
- HAN00057
- HAN00056
- HAN00055
- HAN00054
- HAN00053
- HAN00052
- HAN00051
- HAN00050
- HAN00049
- HAN00048
- HAN00047
- HAN00046
- HAN00045
- HAN00044
- HAN00043
- HAN00042
- HAN00041
- HAN00040
- HAN00039
- HAN00038
- HAN00037
- HAN00036
- HAN00035
- HAN00034
- HAN00033
- HAN00032
- HAN00031
- HAN00030
- HAN00029
- HAN00028
- HAN00027
- HAN00025
- HAN00024
- HAN00023
- HAN00022
- HAN00021
- HAN00020
- HAN00019
- HAN00018
- HAN00017
- HAN00016
- HAN00015
- HAN00014
- HAN00013
- HAN00012
- HAN00011
- HAN00010
- HAN00009
- HAN00008
- HAN00007
- HAN00006
- HAN00005
- HAN00004
- HAN00003
- HAN00002
- HAN00001
- Lab Info
- Laboratory Response Network (LRN)
- Preparation & Planning
- Related Links
- Risk Communicator
- Issue 3
- Issue 2
- Priceless Collaboration for Hurricane Preparedness
- Talking to WHO's John Rainford - New WHO Guidelines
- Emergency Communication Challenges in Hurricane Katrina Response
- Hurricane Readiness in High-Risk Areas: Survey Results
- Elements of a Successful Exercise: Functional vs Tabletop and Beyond
- Collaboration & Communication During Emergency Response
- Public Health Observances
- Calendar of Training Opportunities
- Contributors
- Issue 1
- Introduction to the Risk Communicator
- Social Media & Emergency Communication
- Messaging Is Matter of Trust
- Program Spotlight: Frontlines of the CA Wildfires
- Research Summaries: Summaries of Work from Deborah Glik and Craig Lefebvre
- Risk Communication Opportunities During National Observances
- Upcoming Conferences, Training, and Workshops of Interest to Risk Communicators
- Contributors
- About the Newsletter
- SNAPS
- Social Media
- Surveillance
- Training & Education
- What CDC Is Doing
- What You Can Do
- Blog: Public Health Matters
- What's New
- A - Z Index
SMALLPOX SUPPLEMENTAL FACT SHEET
Investigational Vaccinia Immune Globulin (VIG) Information
The smallpox vaccine is made from a live virus related to smallpox called vaccinia, not smallpox virus (variola). The vaccine stimulates the immune system to react against the vaccinia virus, and develop immunity to it. Immunity to vaccinia also provides immunity to smallpox. For most people, live virus vaccines are safe and effective. Some people, however, are at greater risk for serious side effects from the smallpox vaccine. Vaccinia Immune Globulin (VIG) may help people who share certain serious reactions to the smallpox vaccine. VIG is made from plasma from the blood of people who have immunity to smallpox. If you develop a serious reaction to the smallpox vaccine, it is possible that you will be offered VIG..
VIG Information
- VIG is an immune globulin made from the blood of people who have gotten the smallpox vaccine more than once (usually many times). Antibodies, the part of the blood that gives protection from vaccinia infection, are taken out, purified (cleaned), and stored. The resulting product is VIG. .
- VIG is administered intravenously. The licensed product is call 'VIG-intravenous' (VIG-IV).
- VIG might be used to treat individuals who have developed generalized vaccinia, eczema vaccinatum, or progressive vaccinia after receiving smallpox vaccine.
How is VIG administered?
VIG is given intravenously, by a needle in a vein in the arm (VIG-IV).
Side Effects
- VIG is made from human blood plasma. Products made from human blood may contain infectious agents, such as viruses, that can cause disease. To decrease the chance that such products carry viruses, plasma donors are checked for prior contact with certain viruses, the collected plasma is treated for the presence of certain viruses, which are killed and/or removed from the plasma.
- Immune globulin products like VIG may cause allergic reactions that can be mild or may be serious and cause life-threatening breathing and heart problems. If you have a serious or life-threatening reaction, medical care and drugs are available to treat you.
- People who have a problem making a certain antibody called IgA or who have had a serious allergic reaction to human antibody products before are at risk for an allergic reaction to VIG.
- Most side effects from similar products are mild and do not last for very long. You may experience back pain, chills, headache, muscle pain, joint pain, itching, weakness, fever, nausea, vomiting, abdominal cramps, flushing, tightness of the chest, sweating, changes in blood pressure, dizziness, paleness, shortness of breath, and wheezing. Rashes occur, but rarely.
- Some people experience pain and soreness at or near the site where VIG is given. While this is unpleasant, it is not serious and can be treated with common pain relievers.
- Share
- Add this to...
- Favorites
- Del.icio.us
- Digg
- Google Bookmarks
- Technorati
- Yahoo MyWeb
- Updates
- Subscribe
- Listen
- Page last reviewed March 10, 2009
- Page last updated March 10, 2009
- Content source: Division of Bioterrorism Preparedness and Response (DBPR), National Center for Preparedness, Detection, and Control of Infectious Diseases (NCPDCID), Office of Infectious Diseases
- Email page
- Print page
- Bookmark and share
- Add this to...
- Favorites
- Del.icio.us
- Digg
- Google Bookmarks
- Technorati
- Yahoo MyWeb
View page in
Get email updates
To receive email updates about this page, enter your email address:
Contact Us:
- Centers for Disease Control and Prevention
1600 Clifton Rd
Atlanta, GA 30333 - 800-CDC-INFO
(800-232-4636)
TTY: (888) 232-6348 - Contact CDC-INFO


